The best and worst biopharma CEOs of 2020, selected by STAT+ readers, are Sam Kulkarni of CRISPR Therapeutics and Nick Leschly of Bluebird Bio.
This is one of the most fascinating paired selections in all the years that I’ve been naming best and worst biopharma CEOs.
Kulkarni won best CEO honors for leading a company that is leveraging the CRISPR/Cas-9 gene-editing platform to craft curative treatments for patients with inherited diseases and cancer. In December, CRISPR and its partner Vertex Pharmaceuticals presented early but very encouraging clinical trial results showing that its one-time treatment called CTX001 was capable of curing sickle cell disease and beta-thalassemia.
About the Author Reprints
